Table 1 Characteristics of participants according to the provisional remission criteria
From: Concurrent validity of provisional remission criteria for gout: a dual-energy CT study
All participants (n = 152) | Provisional remission criteria fulfilled (n = 23) | Provisional remission criteria not fulfilled (n = 129) | |
|---|---|---|---|
Age (years), mean (SD) | 58 (11) | 62 (11) | 58 (11) |
Male, n (%) | 140 (92.1) | 20 (97) | 120 (93.0) |
Race, n (%) | |||
White | 98 (64.5) | 16 (70) | 82 (63.6) |
Non-white | 54 (35.5) | 7 (30) | 47 (36.3) |
Duration of gout (years), median (range) | 12 (1–25) | 10 (1–35) | 12 (1–45) |
Allopurinol daily dose, n (%) | |||
300 mg | 124 (84.6) | 21 (91) | 103 (79.8) |
> 300 mg | 28 (18.4) | 2 (9) | 26 (20.2) |
Duration of allopurinol use (years), median (range) | 2.9 (0.2–45) | 3.3 (0.3–27) | 2.8 (0.2–45) |
Serum urate (< 0.36 mmol/L) | 77 (50.7) | 23 (100) | 54 (41.9) |
Tophus (absence) | 104 (68.4) | 23 (100) | 81 (62.8) |
Flares (none in the last 12 months) | 70 (46.1) | 23 (100) | 47 (36.4) |
Pain (due to gout, < 2) | 104 (68.4) | 23 (100) | 81 (62.8) |
Patient global assessment of gout activity (< 2) | 84 (55.2) | 23 (100) | 61 (47.3) |